Dr. Marc Gerdisch, MD
Claim this profileSt Francis Hospital
Studies Tricuspid Valve Disease
Studies Tricuspid Regurgitation
7 reported clinical trials
8 drugs studied
Affiliated Hospitals
Clinical Trials Marc Gerdisch, MD is currently running
Left Atrial Appendage Exclusion
for Stroke Prevention
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
Recruiting1 award N/A2 criteria
ECM Valve Replacement
for Tricuspid Valve Disease
The goal of this pivotal study is to demonstrate the safety and performance of the Cor TRICUSPID ECM (extracellular matrix) Valve (or Cor PEDIATRIC Tricuspid ECM Valve) for the surgical management of tricuspid valve disease and dysfunction in adult and pediatric patients. The main question(s) it aims to answer are: * whether the device may be implanted successfully and safely, and * whether the device effectively treats tricuspid valve disease and dysfunction through 12 months Participants will undergo: * preoperative evaluation * tricuspid valve replacement with the Cor TRICUSPID ECM Valve * postoperative evaluation, including at hospital discharge, 30 days, 6 months, and 12 months, and then annually thereafter through 5 years
Recruiting1 award N/A4 criteria
More about Marc Gerdisch, MD
Clinical Trial Related5 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Marc Gerdisch, MD has experience with
- Cor TRICUSPID ECM Valve
- AtriCure CryoICE & AtriClip LAA Exclusion
- CorMatrix Cor TRICUSPID ECM Valve
- On-X Aortic Heart Valve Replacement
- AtriClip
- AtriClip LAA Exclusion System
Breakdown of trials Marc Gerdisch, MD has run
Tricuspid Valve Disease
Tricuspid Regurgitation
Atrial Fibrillation
Coagulopathy
Left Atrial Appendage Absent
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Marc Gerdisch, MD specialize in?
Marc Gerdisch, MD focuses on Tricuspid Valve Disease and Tricuspid Regurgitation. In particular, much of their work with Tricuspid Valve Disease has involved treating patients, or patients who are undergoing treatment.
Is Marc Gerdisch, MD currently recruiting for clinical trials?
Yes, Marc Gerdisch, MD is currently recruiting for 4 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Marc Gerdisch, MD has studied deeply?
Yes, Marc Gerdisch, MD has studied treatments such as Cor TRICUSPID ECM Valve, AtriCure CryoICE & AtriClip LAA Exclusion, CorMatrix Cor TRICUSPID ECM Valve.
What is the best way to schedule an appointment with Marc Gerdisch, MD?
Apply for one of the trials that Marc Gerdisch, MD is conducting.
What is the office address of Marc Gerdisch, MD?
The office of Marc Gerdisch, MD is located at: St Francis Hospital, Indianapolis, Indiana 46237 United States. This is the address for their practice at the St Francis Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.